Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 3 1Phase 1/2 1Phase 1 1

Status

Not yet recruiting 2Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2INDUSTRY 2

Study Type

Interventional 4

Sponsor

Conditions

Breast Neoplasms 2419Neoplasms 1838Carcinoma, Non-Small-Cell Lung 1591Prostatic Neoplasms 1296Colorectal Neoplasms 1117Lung Neoplasms 981Neoplasm Metastasis 828Multiple Myeloma 793Leukemia, Myeloid, Acute 773Ovarian Neoplasms 673Pancreatic Neoplasms 667Melanoma 660Squamous Cell Carcinoma of Head and Neck 589Recurrence 563Carcinoma, Hepatocellular 562Brain Neoplasms 515Glioblastoma 505Stomach Neoplasms 501Head and Neck Neoplasms 492Triple Negative Breast Neoplasms 471Lymphoma 460Uterine Cervical Neoplasms 444Carcinoma, Renal Cell 426Precursor Cell Lymphoblastic Leukemia-Lymphoma 420Lymphoma, Non-Hodgkin 387Endometrial Neoplasms 377Sarcoma 365Lymphoma, Follicular 357Urinary Bladder Neoplasms 356Lymphoma, Large B-Cell, Diffuse 355

Interventions

enzalutamide 2tislelizumab 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Interventional × mCRPC × 1 year × Clear all
NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting
1,054 enrolled 21 charts 1 FDA

mCRPC

NCT07389187 2026-02-05

Safety and Preliminary Efficacy Evaluation of LC-K76 Plus Anti-PD-1 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)

Shanghai Changzheng Hospital

Phase EARLY_PHASE1 Not yet recruiting
10 enrolled

mCRPC

NCT07104643 2025-08-05

Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer(mCRPC)

TYK Medicines, Inc

Phase 1/2 Not yet recruiting
48 enrolled

mCRPC

NCT07096128 2025-07-31

A Study of [177Lu] Lu-PSMA-XT Injection in Patients With Metastatic Prostate Cancer

Chinese PLA General Hospital

Phase 1 Recruiting
36 enrolled

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡